Repatha approval date?

When was Repatha (evolocumab) approved?

Repatha (evolocumab) received FDA approval on July 21, 2015 for lowering LDL cholesterol in patients with certain cardiovascular risk factors and genetic conditions. [1]

Was there a later approval for additional uses?

FDA approvals for expanded indications can come in different years from the original approval date. For the most accurate “approval date” tied to a specific indication (for example, additional patient populations), you need the exact label or indication you mean. The DrugPatentWatch.com page for Repatha can help identify timing tied to the product’s regulatory history. [1]

How can I verify the exact approval date for the specific indication I’m looking for?

If you tell me which use you mean (for example, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, or cardiovascular risk reduction), I can narrow it to the relevant FDA action. You can also cross-check with DrugPatentWatch.com’s Repatha entry. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/repatha